Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Neurocrine Biosciences Inc., 3 years.
Neurocrine Biosciences Inc.
Director
Fate Therapeutics Inc.
Director
Dare Bioscience Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Dare Bioscience Inc. July 9, 202594.4%
-
Fate Therapeutics Inc. June 3, 202490.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Dare Bioscience Inc. | Grant or award | +38,862 | — | — |
| May 21, 2026 | Neurocrine Biosciences Inc. | Option exercise | +3,318 | — | — |
| May 5, 2026 | Fate Therapeutics Inc. | Option exercise | +25,000 | $1.69 | $42,250 |
| Nov 5, 2025 | Neurocrine Biosciences Inc. | Option exercise | +18,000 | $47.89 | $862,020 |
| Nov 5, 2025 | Neurocrine Biosciences Inc. | Open-market sale | −18,000 | $151.82 | $2,732,760 |
| May 22, 2025 | Neurocrine Biosciences Inc. | Option exercise | +2,869 | — | — |
| May 5, 2025 | Neurocrine Biosciences Inc. | Option exercise | +30,000 | $42.76 | $1,282,800 |
| May 5, 2025 | Neurocrine Biosciences Inc. | Open-market sale | −30,000 | $110.20 | $3,306,000 |
| Aug 15, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −14,250 | $146.69 | $2,090,333 |
| Jan 2, 2024 | Neurocrine Biosciences Inc. | Option exercise | +20,000 | $12.98 | $259,600 |
| Jan 2, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −11,044 | $131.47 | $1,451,955 |
| May 1, 2023 | Neurocrine Biosciences Inc. | Option exercise | +7,625 | $12.71 | $96,914 |
| May 1, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −4,300 | $101.43 | $436,149 |
| Apr 21, 2023 | Neurocrine Biosciences Inc. | Option exercise | +10,765 | $12.71 | $136,823 |
| Apr 21, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −6,034 | $105.04 | $633,811 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.